Barzolvolimab ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05774184 (ClinicalTrials.gov) | May 2023 | 7/3/2023 | A Phase 2 Study of Barzolvolimab in Patients With Eosinophilic Esophagitis | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The EvolvE Study) | Eosinophilic Esophagitis | Biological: barzolvolimab;Drug: Matching Placebo | Celldex Therapeutics | NULL | Not yet recruiting | 18 Years | N/A | All | 60 | Phase 2 | NULL |